By Mary de Wet
PolyPid said Tuesday that it has produced three process-validation batches of D-PLEX, its lead drug candidate to prevent surgical-site infections, putting the company on track to seek regulatory approval.
The Israel-based biopharma company didn’t give a timeline for when it would submit new drug and marketing authorization applications…
Read the full article here
